GENSPEED BIOTECH GMBH

Their core work

Genspeed Biotech is an Austrian SME specializing in rapid diagnostic testing, developing microfluidic-based bioanalytical devices for medical diagnostics. They contribute expertise in device validation, quality management, and bringing nano-enabled diagnostic platforms from lab prototypes to manufacturable products. Their work sits at the intersection of nanotechnology, microfluidics, and photonics — always oriented toward scaling up diagnostic devices for real-world medical use. All three of their H2020 projects are Innovation Actions, confirming their focus on market-ready technology rather than basic research.

What they specialise in

How they've shifted over time

Genspeed's earliest H2020 involvement (R2R Biofluidics, 2015-2019) focused on large-scale micro- and nanofabrication techniques — essentially the manufacturing backbone for diagnostic chips. From 2020 onward, their projects shifted decisively toward the application layer: medical diagnostics via photonics (MedPhab) and next-generation microfluidic test beds with nano-enabled surfaces (NextGenMicrofluidics). The trajectory is clear — from manufacturing process contributor to a company actively shaping the diagnostic device itself, including its validation, regulatory pathway, and time-to-market readiness.

Genspeed is moving up the value chain from fabrication contributor toward owning the diagnostic device development and validation process, making them increasingly relevant as a partner for medical device scale-up projects.

How they like to work

Genspeed always participates as a partner, never as coordinator, which is typical for a focused SME that brings specific technical capabilities to larger consortia. With 45 unique partners across just 3 projects, they operate in large Innovation Action consortia (averaging 15+ partners per project). This means they are experienced in multi-partner, cross-country collaboration and comfortable contributing a defined work package without needing to lead the administrative effort.

Despite only three projects, Genspeed has built a network of 45 unique consortium partners spanning 14 countries — a wide European footprint driven by participation in large-scale Innovation Actions. Their network is weighted toward manufacturing, nanotechnology, and medical device development communities.

What sets them apart

Genspeed occupies a specific niche: they are a biotech SME that understands both the nano-scale science of diagnostic surfaces and the practical requirements of scaling those devices to production. Few SMEs combine hands-on experience with roll-to-roll fabrication, microfluidic device validation, and regulatory readiness for medical diagnostics. For consortium builders, they fill the critical gap between a lab prototype and a manufacturable, validated medical device.

Highlights from their portfolio

• NextGenMicrofluidics
  Their largest funded project (EUR 444K), covering the full chain from nano-enabled surfaces to upscaling, validation, and regulatory readiness for microfluidic devices.
• MedPhab
  A photonics pilot line project that positions Genspeed at the intersection of photonics and medical diagnostics — a strategic diversification from their microfluidics core.
• R2R Biofluidics
  Their first H2020 project, focused on roll-to-roll nanofabrication — the manufacturing foundation that all their subsequent diagnostic device work builds upon.